iTeos Therapeutics (NASDAQ:ITOS) Sees Strong Trading Volume Following Analyst Upgrade

iTeos Therapeutics, Inc. (NASDAQ:ITOSGet Free Report) saw an uptick in trading volume on Monday after HC Wainwright raised their price target on the stock from $44.00 to $46.00. HC Wainwright currently has a buy rating on the stock. 196,203 shares were traded during mid-day trading, a decline of 39% from the previous session’s volume of 322,862 shares.The stock last traded at $17.02 and had previously closed at $17.44.

Separately, Wedbush reissued an “outperform” rating and set a $18.00 price objective (down from $25.00) on shares of iTeos Therapeutics in a research note on Wednesday, March 6th.

Check Out Our Latest Stock Analysis on ITOS

Institutional Investors Weigh In On iTeos Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ITOS. Vanguard Group Inc. increased its holdings in iTeos Therapeutics by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,813,759 shares of the company’s stock valued at $19,861,000 after purchasing an additional 40,407 shares during the last quarter. 683 Capital Management LLC grew its stake in shares of iTeos Therapeutics by 38.5% in the third quarter. 683 Capital Management LLC now owns 810,000 shares of the company’s stock worth $8,870,000 after acquiring an additional 225,000 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in shares of iTeos Therapeutics during the 3rd quarter worth $7,917,000. Barclays PLC lifted its position in shares of iTeos Therapeutics by 2.4% during the 3rd quarter. Barclays PLC now owns 322,322 shares of the company’s stock worth $3,529,000 after purchasing an additional 7,442 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of iTeos Therapeutics by 6.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 278,959 shares of the company’s stock worth $3,055,000 after purchasing an additional 17,090 shares during the last quarter. 97.16% of the stock is owned by institutional investors and hedge funds.

iTeos Therapeutics Stock Performance

The firm has a market capitalization of $601.42 million, a PE ratio of -4.42 and a beta of 1.27. The company’s 50-day moving average price is $12.02 and its 200-day moving average price is $10.97.

iTeos Therapeutics (NASDAQ:ITOSGet Free Report) last posted its quarterly earnings data on Wednesday, March 6th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.18. As a group, analysts anticipate that iTeos Therapeutics, Inc. will post -4.76 earnings per share for the current year.

About iTeos Therapeutics

(Get Free Report)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Read More

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.